Baltimore, MA | March 10-14| Booth #906
Comprehensive genetic solutions across key clinical areas:
Labcorp and Invitae’s genetic testing for rare disease
From exome sequencing to broad panels across pediatric genetics, cardiology, neurology and more, we bridge the gap between clinical presentation and genetic insights. Our combined expertise in genetics delivers the insights providers need to move from uncertainty to answers. Our extensive testing portfolio ensures you have access to the right test for your patients.
Women’s health: Fertility, pregnancy and reproductive genetics
We’re helping healthcare providers deliver confident care for every pregnancy by offering the most comprehensive women's health portfolio including cfDNA (NIPT) screening, carrier screening, prenatal diagnostics, preeclampsia screening and integrated genetic counseling options.
Oncology and hereditary cancer testing
From screening and preventative care to cancer diagnosis and personalized treatments, we are here to support your care across the cancer journey (or cancer care continuum). Labcorp and Invitae offer somatic and hereditary cancer testing, genetic risk panels and genetic counseling support.
Invitae precision medicine solutions
Harness the power of our robust data sets to uncover new insights and advance therapies across the development lifecycle. Explore our services and learn about partnerships to accelerate discovery, clinical research, testing access programs, and real-world evidence.
Advancing genetic medicine through rigorous science
Don’t miss our poster and platform presentations for an opportunity to discuss our latest research and clinical insights. Labcorp is proud to present seven posters at ACMG 2026, showcasing our commitment to advancing the field of medical genetics.
Thursday, March 12, 10:30–11:30 AM (ET)
- (P671) Fifteen years of microarray analysis: hidden benefits of the SNP array
- (P757) The role of deletion and duplication analysis in cystic fibrosis carrier screening
- (P139) Pre-test clinical enrichment refines interpretation of CFTR TG–T with or without R117H haplotypes
Friday, March 13, 10:30–11:30 AM (ET)
- (P758) Gaps in CFTR carrier screening: population diversity and variant representation
- (P080) Universal germline testing of breast cancer as standard of care in a diverse, rural community oncology practice: the UNITY trial
- (P072) Complementary germline and somatic testing in breast cancer care
- (P058) Three-year use of risk-reducing interventions among cancer- free women with germline pathogenic variants in breast cancer predisposition genes
Don’t miss our platform presentation from Dr. Stuart Schwartz, PhD, FACMG:
Wednesday, March 11, 12:15-1:15 pm (ET)
- VUS is not a four-letter word: A better understanding of copy-number variants of unknown significance from examining a large dataset
How can variant interpretation at scale unlock faster answers for rare disease patients?
The diagnostic odyssey for rare disease patients often spans years, causing uncertainty and delayed treatment. At Labcorp, we’re leveraging advanced technology and clinical expertise to transform gene variant interpretation and accelerate the path to diagnosis. Read our featured article in STAT News to discover how scalable variant interpretation is revolutionizing rare disease diagnostics.
How leaders are scaling precision medicine across care settings
In this panel discussion, leaders from Swedish Cancer Institute, Labcorp, and genetics media offered their perspectives on scaling genetic services across diverse settings and preparing for the next era of precision medicine. They shared real-world strategies to expand access, streamline workflows and strengthen collaboration across the care continuum.
Quality, accuracy and scientific rigor – powered by people
Access our on-demand variant interpretation webinars to see how human oversight remains essential even as AI and machine learning take hold
The importance of human expertise: genetic testing from sample to report
Take a look into the critical role of scientists at each stage of the process, including sample processing, sequencing, data analysis, variant classification and report generation. Learn how automation enhances efficiency and consistency, while expert human oversight ensures each result is accurate, reliable, and clinically meaningful.
The importance of human expertise in AI-informed variant interpretation workflows
We explore how AI is helping leverage diverse data sources to improve classification confidence and reduce rates of variants of uncertain significance (VUS). We compare the impact of machine learning-driven insights versus traditional evidence, and how expert oversight ensures that these innovations translate into meaningful clinical outcomes.
Making sense of MAVEs: how machine learning and human expertise are improving variant classification and clinical actionability
Learn how multiplexed assays of variant effect (MAVEs) produce high-throughput functional data, and how machine learning models standardize, validate and integrate those data into germline variant classification. MAVE-based models can be incorporated to reclassify variants, reduce variants of uncertain significance (VUS) and enhance clinical actionability.